Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

Trodelvy dosing is 10 mg/kg IV on days 1 and 8 of 21-day cycles, continued until progression or unacceptable toxicity; pembrolizumab schedules follow prescriber determination. Safety requires ...

Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS ...

US FDA approves Keytruda and Keytruda Qlex, each with Trodelvy as first-line treatment of PD-L1+ (CPS =10) advanced TNBC: Rahway, New Jersey Friday, June 26, 2026, 09:00 Hrs [IST] ...

Two major studies are looking at moving sacituzumab govitecan earlier for metastatic triple-negative breast cancer.

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

The FDA has approved sacituzumab govitecan-hziy as first-line therapy for adults with unresectable locally advanced or ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...

– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy ...

Before the latest perioperative nod in resectable disease, Keytruda has been approved in first-line metastatic head and neck cancer. (Angus Liu/Fierce Pharma) Merck & Co.’s Keytruda has become the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® ...